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NK cells and αβ- and γδ-CTL play important roles in cellular
immunity against tumors. We previously demonstrated that NPC
patients have a quantitative and qualitative deficit in γδ-CTL and
EBV-specific αβ-CTL when compared to normal subjects and NPC
long-term survivors. In this study we report further observations
of a complementary activation of peripheral NK cells in NPC
patients. The NK cells in these patients, compared to those of
healthy subjects and NPC survivors, were preferentially
activated in response to the stimulation of myeloma cell line
XG-7 and expanded in the presence of exogenous IL-2. The
production of IFN-γ was lowest in the patient group, whereas IL-
12, IL-15 and TNF-α were produced in higher levels in patients
than in the donors and survivors. The cytolytic effect of the NK
cells against NPC cells in the patient group was also higher than
that of the donors and survivors. Furthermore, the patients at
later stages of NPC had lower γδ-CTL activity but higher NK
cytotoxicity towards NPC targets, with higher production of
IL-12, IL-15 and TNF-α but lower production of IFN-γ than in
patients at earlier stages. This might be part of a triggered
compensatory re-activation of the innate immunity, believed to
be mediated through various cytokines and chemokines when
adaptive T cell immunity is breached. Together, these data suggest
complementary roles of innate and adaptive immune response in
tumor immunity where NK cells, γδ- and αβ-CTL compensate for
the deficits of one another at different stages of tumor invasion.
(Cancer Sci 2006; 97: 912–919)
NK cells, and αβ- and γδ-CTL are the dominant playersin cellular immunity to tumors.(1) The presence of
cellular disregulation manifested as abnormal expressions on
the surface of tumor cells are potential targets for immune
surveillance by these cytolytic lymphocytes.(2) The effector
function of αβ-CTL of the adaptive immune response is
MHC restricted and hence provides more specific targeted,
albeit delayed, cytotoxicity.(3) NK cells and γδ-CTL are thought
to contribute principally to innate immune surveillance due to
their non-MHC restricted cytotoxicity, which will accommodate
a more rapid response to cellular stress and disregulation
signals that trigger these cells’ cytolytic functions.(4–6) The
escape mechanisms of tumor cells from these cytolytic
lymphocytes depend on the expression of different cell
surface molecules such as inhibitory ligands.(7) The presence
of these inhibitory ligand-mediated escape mechanisms is
essential for the host to control excessive autoimmune reactions
in otherwise healthy individuals.(8) Different inhibitory ligands
are recognized by receptors, such as NKG2A and KIR,
distributed amongst these different cytolytic cells, thus
reducing the chance of the tumor cells’ complete escape from
them.(9–11) The nature of these lymphocytes, taken together,
thus provides a broad defense net at different stages of
cellular immunity as well as broader coverage of cytotoxicity
towards their respective targets.
The cytolytic effect of NK cells mainly occurs through
the granulysin–perforin mechanism after activation of the
appropriate receptors and in the absence of inhibitory ligands
such as MHC class I molecules.(12) Circulating NK cells rec-
ognize and kill cells which express abnormally downregu-
lated levels of MHC class I molecules resulting from stress,
infection or cellular disregulation.(13) However, tumor cells
expressing MHC class I molecules are also susceptible to
NK cytotoxicity when ligands to the NKG2A receptor,
such as MIC and RAE-1, are coexpressed(6,10) providing an
impediment to escape mechanisms depending on MHC class
I alone.
The roles of NK cells and T cells in host immunity are
extensively interdependent through the sharing of cytokines
and chemokines in a complex web of stimulatory and inhib-
itory interactions which remains to be further explored.(14–20)
NK cells are generally believed to take part in early innate
host defense through a non-specific response to inflammatory
cytokines. They are distinguished from T cells in that they
do not partake in adaptive immunity through expression of
rearranged antigen receptors.(21) NK cells do contribute to the
development of the adaptive immune response,(22) but their
role diminishes as the more specific adaptive immune response
begins to mature in the body’s defense. Kasaian et al.(23)
recently demonstrated that IL-21, a product of activated T
cells, can reduce NK cells by antagonizing their survival,
which provides one possible pathway for innate immunity to
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be taken over by adaptive immunity as the immune response
progresses.
NPC is an EBV-associated cancer common in southern
China. We have previously shown that NPC patients display
quantitative and qualitative deficits in γδ-CTL and EBV-
specific αβ-CTL compared to NPC long-term survivors and
healthy donors.(24,25) The deficits were restored in the survi-
vors after successful treatment to remove the tumor. In this
study, we further demonstrate that NPC patients exhibit
preferential activation of NK cells with concomitant increase




Study subjects included 15 active NPC patients, five long-
term survivors who had been in disease-free remission for
5–13 years and five healthy donors. All study subjects were
male ethnic Chinese whose ages coincided with the peak
age incidence of the disease. Diagnosis of NPC patients was
confirmed by characteristic pathology of poorly or undiffer-
entiated carcinoma. The disease stage was defined according to
Ho’s standard.(26) The 15 active NPC patients were divided
into three groups according to their NPC stages, which were
varied from T1N1 to T3N3 (Table 1).
Cytokines, cell lines and cell cultures
All recombinant cytokines were obtained from R&D Systems
(USA). XG-7 is a human myeloma cell line that expresses
both HLA-I (97% with intensity 511) and HLA-II (94% with
intensity 458).(27) This cell line has been demonstrated to be
able to effectively simulate growth of γδ T cells using Hsp70
on its surface.(28) CNE2 and 915 are NPC cell lines. They
were generous gifts of Dr X. Zhang (Su Zhou Medical
College, China) and Dr Y. Zeng (Chinese Academy of
Preventive Medicine, Beijing, China), respectively. XG-7
was cultured in RPMI-1640 medium (Gibco-BRL, USA)
supplemented with 10% FCS (Gibco-BRL) (10% RPMI),
0.2 mM L-glutamine and antibiotics (100 U/mL of penicillin,
100 µg/mL streptomycin, 20 µg/mL garamycin and 100 units
of nystatin) and 1 U/mL rIL-6. The NPC cell lines were
cultured in modified Eagle’s medium (Gibco-BRL) supplemented
with 10% FCS (10% MEC), 0.2 mM L-glutamine and antibiotics.
PBMC obtained from the study subjects were separated
by Ficoll-Hypaque (Pharmacia Biotech, Sweden) according
to standard procedure. CD40-activated B cell lines were
established as described previously.(28)
Ex vivo expansion of non-HLA-restricted tumor-effector 
cells
PBMC were cultured with a γδ T cell stimulant, XG-7, for 10
days. The non-HLA-restricted tumor-effector cells were
expanded ex vivo as described previously.(28,29) Briefly,
1 × 107 of PBMC was mixed with 5 × 106 irradiated (7000
cGy) allogeneic XG-7 cells and incubated in 10% RPMI.
Irradiated XG-7 cells (3 × 106) were added to the cultures
on day 3, 6 and 9. Exogenous rIL-2 (100 U/mL) was added
to the cultures on day 11 and fed every 2–3 days or as needed
thereafter.
Flow cytometry analysis using FACS
Approximately 1 × 106 cells were stained with FITC- or PE-
labeled mAbs specific for CD3, CD34, CD56, Lineage, pan
TCR-αβ, pan TCR-γδ and mouse immunoglobulin G1 (BD
Biosciences, USA) for 30 min at 4°C. After three washes with
phosphate-buffered saline, the stained cells were analyzed
using a flow cytometer (BD Biosciences).
Purification of NK cells and γδ T cells
NK cells and γδ T cells were purified from 4-week expansion
cultures using MACS CD56 and TCR-γδ MicroBeads
(Miltenyi Biotec, Germany). Briefly, approximately 107 cells
in 0.5 mL of phosphate-buffered saline containing 2 mM
EDTA and 0.5% FCS were mixed with 20 µL of the CD56 or
TCR-γδ beads and allowed to stand at 6–10°C for 20 min.
The beads-bound NK cells or γδ T cells were magnetically
separated. The procedure was repeated to ensure the purity of
NK and γδ T cells (>95%).
Detection of cytokine secretion
The production of IFN-γ, TNF-α, IL-15 and IL-12 in XG-7
stimulated cell cultures was detected by ELISA using OptEIA
kits (PharMingen, USA) according to the manufacturer’s
instructions. Levels of these cytokines in supernatant obtained
on day 2, 4, 6, 8 and 10 post-stimulation were quantified
using at least six concentrations of standard cytokines provided
by the kits.
Detection of CTL activity
The CTL activity of the purified NK and γδ T cells was
determined in triplicate by a standard 4 h Calcein AM
release assay (Molecular Probes, USA) in U-bottom 96-well
microplates.(28,30,31) Briefly, triplicate cultures were seeded
with a graded number of purified NK or γδ T cells and 5000
Calcein AM (Molecular Probes) labeled target cells at
effector:target ratios from 30/1 to 0.3/1. The cytolysis of the
targets was determined by measuring Calcein AM FI using
a fluorometer. The maximum release was estimated by
incubating target cells with 5% sodium dodecylsulfate (total
lysis) and the spontaneous release estimated by incubating
the targets in medium alone (target control). The percentage
specific cytolysis was calculated as follows:
Table 1. NPC statuses of 25 study subjects, with disease stages





II (P1) III (P2) IV (P3) II–III
1 T2N1 T3N1 T2N3 T2N1 NA
2 T1N1 T2N2 T3N3 T1N2 NA
3 T1N1 T2N2 T3N3 T2N2 NA
4 T2N1 T3N1 T3N3 T3N2 NA
5 T1N1 T2N2 T2N3 T2N2 NA
Diagnosis of NPC patients was confirmed by characteristic 
pathology of poorly or undifferentiated carcinoma. NA: Not 
applicable.
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Statistical analysis
The significance of differences between groups was analyzed
by paired Student’s t-test.
Results
Preferential activation and expansion of NK cells from 
NPC patients in response to tumor cell stimulator
FACS analysis of freshly prepared PBMC revealed that the
frequencies of CD3–/CD56+ NK cells were similar among
NPC patients, survivors and healthy donors. However, the
percentage of γδ T cells was slightly lower in the patients
than survivors and donors, and CD34+/Lin cells, NK cell
precursors, showed markedly increased frequencies in the
patients than in the other groups (Fig. 1a). PBMC were ex
vivo stimulated with XG-7 cells, a non-HLA restricted tumor
stimulant,(25,28) for 10 days and further cultured in the
presence of exogenous IL-2 thereafter. The number of NK
cells was increased rapidly in the cultures of the patient
groups in response to the tumor cell stimulation, reaching
7.9 ± 1.2 × 106 (mean ± standard deviation, the same below)
on day 10 (Fig. 2a), which was approximately 12- and 24-
fold higher than those in the cultures from survivors
(0.66 ± 0.3 × 106) and donors (0.33 ± 0.3 × 106), respectively
(P < 0.05). Notably, the frequency of NK cells from the
patient groups was markedly higher after 4 weeks of culture,
reaching 38.6% ± 21.5%, as compared to that of survivor
(1.5% ± 1.1%) and donor (0.5% ± 0.2%) groups. However,
no CD34+/Lin– cells were detectable in these cultures (Fig. 1b).
Interestingly, the number of γδ T cells in the cultures from
the patient group was significantly less than those of donors and
survivors after 10 days with tumor cell stimulation (Fig. 2b),
suggesting impaired activation of γδ T cells from the patients.
In the presence of exogenous IL-2, rapid γδ T cell growth
was sustained for approximately 5 weeks in the cultures of
PBMC from survivors and donors, reaching approximately
8.8 × 109 and 5.4 × 109, respectively. However, the number
of γδ T cells in cultures from NPC patients was at least 20-
fold lower than that from survivors and donors (P < 0.01)
(data not shown). After 4 weeks of culture, NK cells from
patients were increased to approximately 1.1 × 108, which was
6- and 10-fold more than those from survivors and donors.
The results showed that NK cells from NPC patients display
markedly enhanced growth after tumor cell stimulation,
whereas their γδ T cell expansion was significantly reduced
as compared with those from the donors and survivors.
Increased cytotoxicity of NK cells from patients to target 
tumor cells
The non-HLA restricted cytotoxicity of NK and γδ T cells to
tumor targets was measured in total cells from 4-week
cultures of study subjects (Fig. 3). The cytotoxicity of
purified NK cells from the cultures of patient groups against
two NPC cell lines, CNE2 and 915, was significantly higher
than other groups, whereas those from healthy donors
showed the lowest cytotoxicity to the tumor targets.
Furthermore, NK cells from survivors showed less cytotoxicity
against the tumor cells, after γδ T cell immunity was
restored, than patients with active disease. Compared to
survivors, however, the cytotoxicity of purified γδ T cells
from patients and donors was markedly reduced. These total
culture cells, purified NK and γδ T cells did not lyse
autologous B cells (data not shown).
Complementary regulation of NK cell and γδ T cell 
immunity associated with the progression of NPC
Cytolytic activities of purified NK and γδ T cells derived
from NPC patients at different disease stages were further
compared (Fig. 4). Patients who had progressed to a later
Specific cytolysis 
Experimental FI  Total lysis FI
Target control FI  Total lysis FI
%  
      











Fig. 1. Phenotypes of PBMC and cell cultures
from study subjects. Phenotypes of fresh
PBMC (a) and the cells harvested in 4-week
cultures (b) from NPC patients, survivors and
healthy donors were analyzed by FACS. γδ T
cells and NK cells were differentiated and
enumerated using a PE-labeled CD3 mAb and
FITC-labeled mAbs specific to TCR-γδ and
CD56, respectively. Numbers of NK cells in
expansion cultures from three groups of
study subjects were determined by total cell
numbers multiplied by the percentage of
CD3–/CD56+ cells in the cultures (c).
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disease stage (group P3) showed more defective γδ T cell
immunity to NPC cell lines than those at earlier disease
stages (groups P1 and P2). The patients in groups P2 and P3
showed stronger cytotoxicity of NK cells to the tumor
targets. Alternately, purified γδ T cells from patients with
earlier NPC status (group P1) showed sustained median levels
of cytotoxic activity against the tumor targets, which were
similar to that from the donors (Fig. 3), but the cytotoxicity
of their NK cells was lower than those from the other patient
groups (groups P2 and P3).
Different profiles of tumor-induced cytokine production 
in the cultures of patients, survivors and donors
Production of cytokines was detected in supernatants
collected at 2-day intervals from the 10-day cultures of the
study subjects (Fig. 5). In response to the stimulation of
tumor cells, culture supernatants of survivors had the highest
level of induced IFN-γ production, followed by that of
donors, and both groups showed significantly higher levels of
IFN-γ production than patients (P < 0.02, Fig. 5a). This IFN-
γ profile was in line with the observation above that much
fewer γδ T cells were activated by the XG-7 stimulation in
the cultures of NPC patients. Interestingly, culture supernatants
from patients showed earlier and higher IL-12p40 production
as compared with those of survivors and donors (Fig. 5b). IL-
12p40 was detectable on day 6 in the cultures from patients,
which was 2 days superior to those from survivors and
donors. In the patient group, the secretion of IL-12p40 reached
the highest level (36 ± 9 pg/mL) after 10 days of culture,
which was significantly higher than that of survivors
(15 ± 6 pg/mL) and donors (9 ± 7 pg/mL) (P < 0.05). The
production of IL-15 (Fig. 5c) and TNF-α (Fig. 5d) was also
higher in the cultures from patients, reaching levels of
29 ± 9 pg/mL and 80 ± 10 pg/mL in day 10 cultures, respectively,
which was significantly higher than those of survivors
(19 ± 5 pg/mL and 54 ± 12 pg/mL) and donors (18 ± 4 pg/
mL and 50 ± 10 pg/mL) (P < 0.05).
Tumor-induced cytokine profiles varied in NPC patients 
with different disease status
Further analysis revealed that the production of cytokines
induced by tumor cell stimulation was varied in patients with
different disease status (Fig. 6). The cultures from patients
who had less disease progression (group P1) showed higher
production of IFN-γ but lower production of IL-12p40, IL-15
and TNF-α than those from patients at later stages (groups
P2 and P3). The level of IFN-γ at day 10 of culture from
group P1 was 115 ± 18 pg/mL, which was significantly higher
than that of groups P2 and P3 (73 ± 9 pg/mL and 66 ± 13 pg/
mL, P < 0.05). However, levels of IL-12, IL-15 and TNF-α
in day 10 cultures from group P1 were 30 ± 5 pg/mL,
22 ± 6 pg/mL and 73 ± 11 pg/mL, respectively, which were
much lower than those from groups P2 (39 ± 7 pg/mL,
37 ± 7 pg/mL and 82 ± 6 pg/mL) and P3 (39 ± 7 pg/mL,
28 ± 6 pg/mL and 84 ± 9 pg/mL). These results were consistent
with those compared to survivors and donors (Fig. 5). The
cytokine profile of patients with earlier disease status (group
P1) was comparable to that of donors than those of patients
at later disease stages (groups P2 and P3).
Discussion
In our previous studies on NPC patients, it was observed that
both patients’ EBV-specific αβ-CTLs and tumor cytolytic γδ-
CTLs suffer from reductions in cell quantity as well as their
respective cytolytic effects against tumor cells.(24,25) Moreover,
increased deficits of these cells were also observed during
the progression of the tumor. In this study, we further
investigated NK cells, another important antitumor immune
cell type, and found that although both EBV-specific αβ-
CTLs and tumor cytolytic γδ-CTLs appeared to have been
breached, NK cells were indeed preferentially activated in
these patients. Their cytotoxicity against NPC cells was also
increased, accompanied by impaired antitumor function of γδ
T cells, as compared to the NK cells from healthy donors. In
contrast, when the tumor has been removed and successfully
treated, as reflected in the survivors, the reverse is observed,
where γδ- and αβ-CTLs appear to be the dominant antitumor
immune cells with increased cytotoxicity towards tumor
Fig. 2. Activation of NK and γδ T cells in PBMC cultures stimulated
with tumor cell line XG-7. PBMC (10 × 106 cells) from NPC patients,
survivors and donors were stimulated with XG-7 and cultured for
10 days. The numbers of NK cells (a) and γδ T cells (b) were determined
every 2 days by FACS using PE-labeled CD3 mAb and FITC-labeled
mAbs specific to TCR-γδ and CD56.
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cells. Our findings suggest a complementary activation of
NK cell-mediated immunity in these NPC patients.
In general, the progression of immune response is sequen-
tially activated from innate to adaptive immunity. NK and γδ
T cells, which are broadly cytolytic, initially play dominant roles
before target-specific αβ T cells take over. It is thus prob-
able that the reverse is true when adaptive immunity is breached
by tumors, especially in view of the intercommunication
Fig. 3. Cytolytic activities of total cultured
cells, purified NK and γδ T cells derived from
study subjects against tumor targets. Cytotoxicity
of total cultured cells, purified NK and γδ T
cells was determined by seeding a graded
number of these effector cells against 5000
of the indicated Calcein AM-labeled target
cells (CNE2 and 915) at an effector:target
ratio from 30:1 to 1:1, and expressed as a
percentage of specific target cell lysis.
Fig. 4. Cytotoxicity of purified NK and γδ T
cells derived from NPC patients with different
disease status against tumor targets.
Cytotoxicity of purified NK and γδ T cells
against NPC targets was determined as
described in Figure 3, and compared
between NPC patients with disease status II
(P1), III (P2) and IV (P3).
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between these cells through molecules such as cytokines
and chemokines. Patients at earlier stage II of NPC (group P1)
had higher γδ-CTL cytotoxicity towards NPC targets than
patients at later stages III and IV (groups P2 and P3). Conversely,
their respective NK cell cytotoxicity was lower than their
later stage counterparts. These results suggest that γδ-CTLs
were probably recruited first as part of the complementary
immune response as the adaptive immunity, that is, specific
αβ-CTLs, was first breached by the tumor cells. With the
progression of the tumor disease, the immune response elicited
by γδ T cells began to show deficiency. Our current observation
that enhanced immune response mediated by NK cells in
patients might reflect some potential compensatory mechanisms.
In patients at a more progressed disease stage (group P3),
γδ T immunity against the tumor targets was further defected,
but not accompanied with continually increased NK cell
cytolytic activity toward the tumors, which suggest that the
remobilized innate immunity would be also exhausted by the
tumors at the later stage of the disease.
In the present study, NK cells are expanded by co-cultures
of PBMC from NPC patients with a tumor stimulator, XG-7.
There is evidence that tumor-cytolytic NK cells can be
expanded ex vivo by co-culture of PBMC obtained from adult
and pediatric acute lymphoid leukemia patients with a feeder
cell line RPMI-8866.(32) It is still not clear why NK cells
could be expanded in ex vivo cultures of PBMC from these
patients. Interestingly, numbers of CD34+/Lin– cells, a pre-
cursor of NK cells, were markedly higher in PBMC taken
Fig. 5. Cytokine profiles in study subjects’
PBMC cultures stimulated with XG-7 cells.
PBMC (10 × 107 cells) from NPC patients,
survivors and donors were stimulated with
XG-7 and cultured for 10 days in the absence
of exogenous IL-2. The culture supernatants
were collected every 2 days for determination
of IFN-γ (A), IL-12p40 (B), IL-15 (C) and TNF-α
(D) by ELISA.
Fig. 6. Cytokine productions in response to
the stimulation of XG-7 cells in PBMC cultures
from NPC patients with different disease
statuses. Production of IFN-γ (A), IL-12p40 (B),
IL-15 (C) and TNF-α (D) in PBMC cultures from
NPC patients with different disease statuses
of II (P1), III (P2) and IV (P3) were tested by
ELISA.
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from patients than those from survivors and donors in our
study (Fig. 1a). Markedly increased CD34+ cells were also
observed in patients with acute myelogenous leukemia.(33–36)
Further study is required to elucidate if the successful ex vivo
expansion of NK cells in these patients is associated with the
increase numbers of CD34+ cells in their blood circulation.
Although the mechanism leading to this resurgence of
NPC cytotoxic NK cells is not clear, cytokines produced in
the cultures upon stimulation of tumors seem to be involved
in immune regulation. The reduced level of IFN-γ, an impor-
tant cytokine for regulating immune response, was observed
in cultures of patient groups (Fig. 3a). This is probably attribut-
able to the decreased total numbers of effector cells in the
cultures, as IFN-γ is produced by both T cells and NK cells.
Increased levels of IL-12, IL-15 and TNF-α were detected in
the patient group, compared to those of the survivors and
donors (Fig. 5b–d). As IL-12 is an activator for both NK cells
and T cells,(37–39) the increased level of this cytokine might be
a signal indicating T cell immunity failure, thus triggering
the response of NK cell activation. On the other hand, IL-12
receptors on macrophages are primed by IFN-γ.(40) The
reduced level of IFN-γ in patient groups might also contri-
bute indirectly to the increase of IL-12 in the cultures by
reducing the amount of IL-12 binding receptor. IL-15 is
known to be important for activation and growth of NK cells,
and it is also able to improve cytolytic activity of NK
cells.(41,42) The rapid expansion of NK cells with higher cytotoxicity
to tumor target cells in the cultures from patient groups might
be partly attributed to the increased IL-15 production. The
upregulation of TNF-α might be a result of NK cell prolifera-
tion and activation, as it is a product of activated NK cells.
Furthermore, this cytokine can promote NK cell-mediated
killing.(43,44) Increased levels of TNF-α in cultures from
patient groups might alternatively enhance the cytolytic abil-
ity of NK cells purified from these cultures. Distinct cytokine
profiles were also observed in three groups of patients with
different NPC status, in which patients with earlier stage
disease showed a cytokine profile closer to that of healthy
donors than those with later stage disease (Fig. 6). Notably,
these cytokine profiles were accompanied with lower γδ T
and higher NK cell activities in cultures from patient groups,
but higher γδ T and lower NK cell activities in cultures from
survivors and donors, suggesting that these cytokines might
play roles in the complementary regulation between NK cells
and T cells.
Although the mechanism of complementary regulation of
innate and adaptive immunity remains to be elucidated, we
have demonstrated that NK cells can be preferentially acti-
vated and expanded ex vivo, when the immune responses
mediated by αβ- and γδ-CTLs are breached in NPC patients.
Further work is underway to investigate the roles of other
immune cells, such as antigen-presenting cells, NKT cells,
and other cytokines, in regulating the immune system to
achieve effective immunity against tumors and infections.
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